BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$9.96-1.29%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · BCRX
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | 940.6 | 874.8 | 450.7 | 331.4 | 270.8 | 157.2 | 17.8 | 48.8 | 20.7 | 25.2 | 26.4 | 48.3 | 13.6 | 17.3 | 26.3 | 19.6 |
| Total Revenues | — | — | — | — | — | — | — | — | — | 25.2 | 26.4 | 48.3 | 13.6 | 17.3 | 26.3 | 19.6 |
| Cost of Revenues | 20.9 | 19.1 | 12.3 | 4.5 | 6.4 | 7.2 | 1.6 | 3.7 | 1.1 | — | — | — | — | — | 0.1 | 0.1 |
| Operating Expenses & Income | ||||||||||||||||
| Selling, General & Admin | 337.3 | 348.6 | 266.1 | 214.1 | 159.4 | 118.8 | 67.9 | 37.1 | 29.5 | 13.9 | 11.3 | 13.0 | — | — | — | — |
| R&D Expenses | 197.8 | 166.1 | 174.6 | 216.6 | 253.3 | 208.8 | 123.0 | 107.1 | 84.9 | 67.0 | 61.0 | 72.8 | 51.8 | 41.9 | 49.2 | 57.2 |
| Operating Income | (313.2) | 341.0 | (2.5) | (103.7) | (148.4) | (177.7) | (174.8) | (99.5) | (94.2) | (57.4) | (48.6) | (39.4) | (45.8) | (30.7) | (33.9) | (49.6) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | 78.9 | 98.5 | 108.2 | 99.1 | 59.3 | 14.5 | 11.9 | 9.2 | 8.6 | 6.5 | 5.2 | 5.0 | 4.8 | 4.7 | 3.8 |
| Other Non-Operating Income / Expenses | (68.0) | (73.6) | (84.4) | (122.5) | (95.9) | — | — | — | — | — | — | — | — | — | — | — |
| EBT, Incl. Unusual Items | (381.2) | 267.4 | (87.0) | (226.2) | (244.4) | (181.8) | (182.8) | — | — | — | — | — | — | — | — | — |
| Income Tax Expense | 3.5 | 3.5 | 1.9 | 0.3 | 2.7 | 2.3 | 0.0 | 0.0 | 0.0 | 0.0 | — | — | 17.3 | — | — | — |
| Net Income | ||||||||||||||||
| Net Income | (384.7) | 263.9 | (88.9) | (226.5) | (247.1) | (184.1) | (182.8) | (108.9) | (101.3) | (65.8) | (55.1) | (43.0) | (45.2) | (30.1) | (39.1) | (56.9) |
| Per Share | ||||||||||||||||
| Basic EPS | (1.51) | 1.26 | (0.43) | (1.18) | (1.33) | (1.03) | (1.09) | — | — | — | — | — | — | — | — | — |
| Diluted EPS | (1.45) | 1.21 | (0.43) | (1.18) | (1.33) | (1.03) | (1.09) | — | — | — | — | — | — | — | — | — |
| Revenue per Share | 3.55 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 254.5 | 209.9 | 206.7 | 192.2 | 185.9 | 179.1 | 167.3 | — | — | — | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | 265.2 | 218.6 | 206.7 | 192.2 | 185.9 | 179.1 | 167.3 | 115.6 | 103.2 | 84.5 | 73.7 | 72.9 | — | — | — | — |
| Supplemental | ||||||||||||||||
| EBITDA | — | 342.4 | (1.3) | (102.1) | (147.0) | (176.9) | (174.0) | (98.7) | (93.5) | (56.7) | (48.1) | (39.3) | (45.6) | (30.4) | (33.3) | — |
| EBIT | (313.2) | 341.0 | (2.5) | (103.7) | (148.4) | (177.7) | (174.8) | (99.5) | (94.2) | (57.4) | (48.6) | (39.4) | (45.8) | (30.7) | (33.9) | (49.6) |
| Effective Tax Rate | -0.9% | — | — | -0.1% | -1.1% | -1.2% | 0.0% | — | — | — | — | — | — | — | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.